UBS Group’s ResMed RMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $273K | Hold |
1,400
| – | – | ﹤0.01% | 6604 |
|
|
2026
Q1 | $314K | Hold |
1,400
| – | – | ﹤0.01% | 6378 |
|
|
2025
Q4 | $337K | Sell |
1,400
-7,800
| -85% | -$1.99M | ﹤0.01% | 6290 |
|
|
2025
Q3 | $2.52M | Buy |
9,200
+1,400
| +18% | +$382K | ﹤0.01% | 4744 |
|
|
2025
Q2 | $2.01M | Buy |
7,800
+400
| +5% | +$95.4K | ﹤0.01% | 4812 |
|
|
2025
Q1 | $1.66M | Buy |
7,400
+2,600
| +54% | +$607K | ﹤0.01% | 4865 |
|
|
2024
Q4 | $1.1M | Buy |
+4,800
| New | +$1.16M | ﹤0.01% | 5230 |
|
|
2024
Q3 | – | Sell |
-69,300
| Closed | -$13.3M | – | 9978 |
|
|
2024
Q2 | $13.3M | Sell |
69,300
-15,700
| -18% | -$3.19M | ﹤0.01% | 2007 |
|
|
2024
Q1 | $16.8M | Sell |
85,000
-95,419
| -53% | -$17.5M | ﹤0.01% | 1830 |
|
|
2023
Q4 | $31M | Buy |
+180,419
| New | +$27.7M | 0.01% | 1284 |
|
|
2020
Q1 | – | Sell |
-5,600
| Closed | -$868K | – | 8330 |
|
|
2019
Q4 | $868K | Sell |
5,600
-2,000
| -26% | -$288K | ﹤0.01% | 4339 |
|
|
2019
Q3 | $1.03M | Buy |
+7,600
| New | +$996K | ﹤0.01% | 3945 |
|
|
2019
Q1 | – | Sell |
-2,300
| Closed | -$262K | – | 8091 |
|
|
2018
Q4 | $262K | Buy |
2,300
+1,200
| +109% | +$129K | ﹤0.01% | 4747 |
|
|
2018
Q3 | $127K | Sell |
1,100
-100
| -8% | -$11K | ﹤0.01% | 5378 |
|
|
2018
Q2 | $124K | Buy |
1,200
+1,000
| +500% | +$101K | ﹤0.01% | 5288 |
|
|
2018
Q1 | $20K | Buy |
+200
| New | +$18.9K | ﹤0.01% | 6416 |
|
|
2017
Q2 | – | Sell |
-130
| Closed | -$9K | – | 7930 |
|
|
2017
Q1 | $9K | Sell |
130
-800
| -86% | -$55.3K | ﹤0.01% | 6680 |
|
|
2016
Q4 | $58K | Buy |
+930
| New | +$57K | ﹤0.01% | 5707 |
|
|
2016
Q1 | – | Sell |
-100
| Closed | -$5K | – | 8078 |
|
|
2015
Q4 | $5K | Sell |
100
-2,000
| -95% | -$113K | ﹤0.01% | 7700 |
|
|
2015
Q3 | $107K | Sell |
2,100
-26,520
| -93% | -$1.43M | ﹤0.01% | 5182 |
|
|
2015
Q2 | $1.61M | Buy |
28,620
+28,520
| +28,520% | +$1.8M | ﹤0.01% | 3184 |
|
|
2015
Q1 | $7K | Sell |
100
-2,920
| -97% | -$190K | ﹤0.01% | 7918 |
|
|
2014
Q4 | $169K | Buy |
+3,020
| New | +$158K | ﹤0.01% | 5199 |
|
Other funds holding RMD
UBS Group's RMD Position: Q2 2026 in Review
UBS Group increased its ResMed (RMD) stake by 77% in Q2 2026, buying an estimated $117M and bringing the position to 1,289,300 shares worth $251M. The position accounts for 0.03% of the portfolio, ranked #548.
UBS Group first reported a position in RMD in Q4 2014 and has held it in 47 quarters since. 889 funds tracked by Wall St. Rank hold RMD as of Q2 2026.
- UBS Group held 1,289,300 shares of ResMed worth $251M as of Q2 2026.
- UBS Group bought 562,489 ResMed shares in Q2 2026, an estimated $117M.
- ResMed made up 0.03% of UBS Group's portfolio in Q2 2026, its #548 holding.
- UBS Group first reported a position in ResMed in Q4 2014 and has held it in 47 quarters since.
- 889 funds tracked by Wall St. Rank held ResMed as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.